Journal profile · RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Nuclear Medicine and Molecular Imaging
ISSN 1869-3474 · eISSN 1869-3482 · Springer Nature · 6 issues per year
Nuclear Medicine and Molecular Imaging: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.3 (journal website); hybrid open access; APC about USD 4,090; median 71 days to acceptance (110 articles, last 24 months); 79 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Nuclear Medicine and Molecular Imaging is published by Springer Nature and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Medical Imaging Techniques and Applications, Radiopharmaceutical Chemistry and Applications and Radiomics and Machine Learning in Medical Imaging, together about 36.7% of its articles. Its main subfields are Radiology, Nuclear Medicine and Imaging. (generated from OpenAlex topic counts and CAS ranking data)
Nuclear Medicine and Molecular Imaging (Nucl Med Mol Imaging) is an official journal of the Korean Society of Nuclear Medicine, which bimonthly publishes papers on February, April, June, August, October, and December about nuclear medicine and related sciences such as radiochemistry, radiopharmacy, dosimetry and pharmacokinetics / pharmacodynamics of radiopharmaceuticals, nuclear and molecular imaging analysis, nuclear and molecular imaging instrumentation, radiation biology and radionuclide therapy. The journal specially welcomes works of artificial intelligence applied to nuclear medicine. The journal will also welcome original works relating to molecular imaging research such as the development of molecular imaging probes, reporter imaging assays, imaging cell trafficking, imaging endo(exo)genous gene expression, and imaging signal transduction. Nucl Med Mol Imaging publishes the following types of papers: original articles, reviews, editorials, interesting images, and letters to the editor. The Korean Society of Nuclear Medicine (KSNM) KSNM is a scientific and professional organization founded in 1961 and a member of the Korean Academy of Medical Sciences of the Korean Medical Association which was established by The Medical Services Law. The aims of KSNM are the promotion of nuclear medicine and cooperation of each member. The business of KSNM includes holding academic meetings and symposia, the publication of journals and books, planning and research of promoting science and health, and training and qualification of nuclear medicine specialists.
From the journal's Aims & Scope
Research area (LetPub): RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Editor-in-chief Hee-Seung HenryPublisher website
Editorial board by country: 1 in mainland China (about 3%); most named South Korea 19, United States 5, Japan 2, Germany 2, Mainland China 1 (33 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Medical Imaging Techniques and ApplicationsMedicine18.1%
- Radiopharmaceutical Chemistry and ApplicationsMedicine11.5%
- Radiomics and Machine Learning in Medical ImagingMedicine7.1%
- Medical Imaging and Pathology StudiesMedicine7.1%
- Thyroid Cancer Diagnosis and TreatmentMedicine5.7%
- Cardiac Imaging and DiagnosticsMedicine4.1%
- Neuroendocrine Tumor Research AdvancesMedicine3.9%
- Prostate Cancer Treatment and ResearchMedicine3.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Radiology, Nuclear Medicine & Medical Imaging | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Radiology, Nuclear Medicine & Medical Imaging | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
EmbaseCASPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 2.3Publisher website ·
- 5-year impact factor (publisher) 2025
- 1.9Publisher website ·
- CiteScore 2026-06
- 3LetPub ·
- SJR 2026-06
- 0.48LetPub ·
- SNIP 2026-06
- 0.72LetPub ·
- h-index
- 43OpenAlex ·
- i10-index
- 348OpenAlex ·
- 2-year mean citedness
- 1.85OpenAlex ·
- Self-citation rate
- 4.3%LetPub ·
- Share of gold OA articles
- 15.44%LetPub ·
Volume
- Articles per year
- 51LetPub ·
- Downloads per year (publisher) 2025
- 120,800Publisher website ·
Articles by year OpenAlex count · 1,644 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 91 | 28 | 22 |
| 2025 | 79 | 70 | 123 |
| 2024 | 70 | 70 | 298 |
| 2023 | 46 | 46 | 266 |
| 2022 | 209 | 64 | 457 |
| 2021 | 131 | 53 | 329 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
71 daysMedian, submission to acceptance · P25–P75 49 days – 115 days
- Acceptance to online
- median 18 days (110 articles)
- Submission to online
- median 90 days
- Sample
- 110 articles with submission and acceptance dates (184 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to first decision
- 9 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,090 / EUR 3,090 / GBP 2,690 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open access publishing
To find out more about publishing your work Open Access in Nuclear Medicine and Molecular Imaging, including information on fees, funding and licences, visit our Open access publishing page.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Nature
- Frequency
- 6 issues per year
- ISSN
- 1869-3474
- Electronic ISSN
- 1869-3482
- Society / sponsor
- Korean Society of Nuclear Medicine
- Latest issue on the website
- Volume 60, Issue 4 (August 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
FAQ
Frequently asked questions about Nuclear Medicine and Molecular Imaging
What CAS zone is Nuclear Medicine and Molecular Imaging in?
In the 2025 upgraded edition of the CAS Journal Ranking, Nuclear Medicine and Molecular Imaging is in Zone 4 of Medicine, and in Zone 4 of the minor category Radiology, Nuclear Medicine & Medical Imaging. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Nuclear Medicine and Molecular Imaging?
The journal's website gives an impact factor of 2.3 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 3, h-index 43.
How long does peer review take at Nuclear Medicine and Molecular Imaging?
Based on the dates recorded on 110 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 71 days (interquartile range 49–115 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Nuclear Medicine and Molecular Imaging based?
Of the 33 board members whose country the journal's board page names, 1 (about 3%) are in mainland China; the countries named most often are South Korea (19), United States (5) and Japan (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Nuclear Medicine and Molecular Imaging?
According to LetPub and DOAJ records, Nuclear Medicine and Molecular Imaging is indexed in ESCI and Scopus. The journal's website also lists Embase and CAS; that list has not been checked against each database.
Is Nuclear Medicine and Molecular Imaging open access, and what is the APC?
Nuclear Medicine and Molecular Imaging is a hybrid journal. For open-access publication: APC about USD 4,090.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .